The National Institutes of Health, Bethesda, Maryland, United States says more than three million people suffer from gallstones disease in the United States every year. A study done by researchers at the Tulane University, New Orleans, United States shows 23 percent higher risk of the development of coronary heart disease (CHD) with gallstone disease in an individual.
Researchers conducted a meta-analysis study involving 842,553 patients and 51,123 coronary heart disease patients. Researchers investigated the history of gallstone disease among coronary heart disease patients. Their meta-analysis results show 23 percent higher risk of the development of coronary heart disease (CHD) in a gallstone disease patient compared to a patient without gallstone disease. The study also found that the risk of coronary heart disease remains even though a gallstone disease patient was without common risk factors associated with coronary heart diseases such as diabetes (or high sugar or glucose levels), high blood pressure (or BP hypertension), obesity or overweight. The study suggests three percent of men and six percent of women are with a history of gallstones. The general characteristics of a patient with a history of gallstones are
Authors of the study say the health of a gallstone disease patient should be monitored closely for coronary heart disease. Authors say their study was the first study showing an association between gallstones disease and cardiovascular disease in the United States. But this study was not showing cause and effect relationship.
Senior author of the study was Dr. Lu Qi, professor of epidemiology, Tulane University New Orleans, Louisiana, United States. The study findings were published on August 29, 2017, in the Arteriosclerosis, Thrombosis, and Vascular Biology. Title of the article was "Gallstones and Risk of Coronary Heart Disease: Prospective Analysis of 270,000 Men and Women From 3 US Cohorts and Meta-Analysis."
A canakinumab drug clinical study done by Swiss pharma company Novartis AG shows prevention of cardiac attacks by reducing inflammation levels. The trials were conducted among 10,000 patients with a prior heart attack or inflammatory atherosclerosis disease.
Among patients with 150 mg doses of canakinumab, 15 percent risk reduction to major adverse cardiovascular events such as nonfatal stroke, nonfatal myocardial infarction or cardiovascular death was observed. Trials also show canakinumab drug can prevent deaths from lung cancer apart from prevention of cardiac attacks. But more studies are required to show the effects of canakinumab drug in treating lung cancer. Fewer patients or an insignificant number of patients died under treatment of canakinumab group compared with patients under placebo group.
Currently, canakinumab drug was being marketed under the name Ilaris to treat rare and inherited diseases such as childhood form of arthritis. The drug costs about $200,000 a year in the United States. Novartis is planning to take approval of canakinumab drug for the treatment of heart diseases in this year itself.
The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. Published article is not a medical advice by the OWNER of "Diabetes News Chronicle" website or by the AUTHOR of the article.
Published by Jammi Vasista, Chennai, India.